Abstract:OBJECTIVE: To testify that the asialoorosomucoid (ASOR) prepared by us has liver‐targeting specificity and to investigate its pharmacokinetic characteristics.METHODS: The distribution of 125I‐ASOR in vivo was determined by single photon emission computed tomography (SPECT) and immunohistochemical technique after 125I‐ASOR was injected into Sprague‐Dawley (S–D) rats through their caudal veins. In vitro, different doses of pEGFP‐N1 plasmid were transfected into both HepG2 cells and HT1080 cells with the use of ASOR‐poly‐L‐lysine. At 24 and 48 h after transfection, the expression of green fluorescent protein (GFP) was determined under fluorescent microscope. Pharmacokinetic parameters were calculated according to two‐compartment open system model with first‐order kinetics.RESULTS: SPECT images showed that 125I‐ASOR was located only in liver/stomach and root of caudal vein / bladder at 10 min after injection. The 125I‐ASOR radioactivities of organs taken out from S–D rats were different at different times, and about 63% of 125I‐ASOR was located in the liver at 10 min after injection. At 30 min after injection a peak of radioactivity was seen in stomach. The times of these two radioactivity peaks were different. Immunohistochemical study of liver frozen sections showed that ASOR was combined mainly with hepatocyte membrane, especially in areas with rich blood flow. In vitro study showed that ASOR targeted specifically cells with asialoglycoprotein receptor (ASGr). GFP expression was detected in HepG2 cells but not in HT1080 cells. Furthermore, the more quantity of pEGFP‐N1 transfected and the longer expression time, the higher GFP expression level was in HepG2 cells. The 125I‐ASOR pharmacokinetics equation for liver was Ct = 662216e−3.362t + 8896e−2343t. 125I‐ASOR was excreted from liver slowly after an initial rapid decrease. The pharmacokinetic equation for stomach was Ct = –114815e−1.7t + 1148153e−15t and the half‐life of 125I‐ASOR in stomach was 4.62 h.CONCLUSIONS: ASOR prepared by us could be an efficient gene transfer vector, ASOR was distributed mainly in the liver and stomach and had high targeting specificity to hepatocytes or hepatic originating cells.

Differential Uptake of Antisense Oligonucleotides in Mouse Hepatocytes and Macrophages Revealed by Simultaneous Two-Photon Excited Fluorescence and Coherent Raman Imaging

High-Resolution Visualisation of Antisense Oligonucleotide Release from Polymers in Cells

Localization of unlabeled bepirovirsen antisense oligonucleotide in murine tissues using in situ hybridization and CARS imaging

Safety and Tolerability of GalNAc3-Conjugated Antisense Drugs Compared to the Same-Sequence 2′-O-Methoxyethyl-Modified Antisense Drugs: Results from an Integrated Assessment of Phase 1 Clinical Trial Data

Tissue pharmacokinetics of antisense oligonucleotides

Disposition and Pharmacokinetics of a GalNAc3-Conjugated Antisense Oligonucleotide Targeting Human Lipoprotein (a) in Monkeys.

Targeting Specificity and Pharmacokinetics of Asialoorosomucoid, a Specific Ligand for Asialglycoprotein Receptor on Hepatocyte

In Situ Tracking the Intracellular Delivery of Antisense Oligonucleotides by Fluorescein Doped Silica Nanoparticles

High-resolution visualization and quantification of nucleic acid–based therapeutics in cells and tissues using Nanoscale secondary ion mass spectrometry (NanoSIMS)

Cytoplasmic and Nuclear Accumulation of Antisense Oligomers Incubated As Streptavidin Delivery Nanoparticles

Antisense oligonucleotides: absorption, distribution, metabolism, and excretion

Understanding Antisense Oligonucleotide Efficiency in Inhibiting Prokaryotic Gene Expression

N-Acetylgalactosamine-Conjugated Antisense Oligonucleotides Designed as Inhibitors of ABCB1: Coping with Multidrug Resistance in Hepatocellular Carcinoma

Nonclinical Pharmacokinetics Study of OLX702A-075-16, N-Acetylgalactosamine Conjugated Asymmetric Small Interfering RNA

Modified ASO Conjugates Encapsulated with Cytidinyl/cationic Lipids Exhibit More Potent and Longer-Lasting Anti-Hcc Effects

Evaluating the oral delivery of GalNAc-conjugated siRNAs in rodents and non-human primates

Lipid nanoparticle delivery limits antisense oligonucleotide activity and cellular distribution in the brain after intracerebroventricular injection

Liver-Targeted Delivery of Oligonucleotides with N-Acetylgalactosamine Conjugation

Targeting the transferrin receptor to transport antisense oligonucleotides across the mammalian blood-brain barrier

RNA toehold switch-based reporter assay to assess bacterial uptake of antisense oligomers

Organ/Cell-Selective Intracellular Delivery of Biologics via N -Acetylated Galactosamine-Functionalized Polydisulfide Conjugates